Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia — REACTS

Severe Aplastic Anemia (SAA) Clinical Trial

Official title:
A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS)

Status Active, not recruiting

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with SAA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04328727
Study type	Interventional
Source	Novartis
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 4, 2020
Completion date	December 9, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00604201` - Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome	Phase 2
Completed	`NCT01891994` - Extended Dosing With Eltrombopag for Severe Aplastic Anemia	Phase 2
Completed	`NCT00001626` - Comparing Therapies for the Treatment of Severe Aplastic Anemia	Phase 2
Recruiting	`NCT04409080` - REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy	Phase 1/Phase 2
Recruiting	`NCT03520647` - Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis	Phase 2
Completed	`NCT01900119` - A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia
Withdrawn	`NCT05323617` - Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy	Phase 2